Zou, Yuanxi http://orcid.org/0000-0003-0547-390X
Nedelman, Jerry
Lombardi, Antonio
Pappas, Frances
Karlsson, Mats O.
Svensson, Elin M. http://orcid.org/0000-0002-0093-6445
Funding for this research was provided by:
Department of Foreign Affairs and Trade, Australian Government
Bill and Melinda Gates Foundation (OPP1129600)
Foreign, Commonwealth and Development Office
Bundesministerium für Bildung und Forschung
Irish Aid
Ministerie van Buitenlandse Zaken
United States Agency for International Development
Article History
Accepted: 20 July 2022
First Online: 30 September 2022
Declarations
:
: This study was a collaborative work between Uppsala University and TB Alliance, supported by TB Alliance (Global Alliance for TB Drug Development) with funding from Australia’s Department of Foreign Affairs and Trade, Bill and Melinda Gates Foundation [OPP1129600], the Foreign, Commonwealth and Development Office (United Kingdom), Germany’s Federal Ministry of Education and Research through KfW, Irish Aid, the Netherlands Ministry of Foreign Affairs, and the US Agency for International Development.
: The authors declare that they have no competing interests. JN, AL, and FP are employees of TB Alliance, the organization developing pretomanid. ES is involved in development of multiple novel anti-tuberculosis compounds through the UNITE4TB consortium.
: This study was performed in line with the principles of the Declaration of Helsinki and the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice: Consolidated Guidance (E6).
: Written informed consent was obtained from all the participants in the study.
: Not applicable.
: The data of this study are not openly available due to sensitivity issues.
: The NONMEM model code is available in the ESM.
: Not applicable.